Skip to main content

Market Overview

Sandwich Chain Jimmy John's In Hot Water With FDA

Share:
Sandwich Chain Jimmy John's In Hot Water With FDA

Jimmy John's received a letter from the U.S. Food and Drug Administration in which the sandwich chain was blasted for a pattern of selling poor quality food, according to Food Business News.

What Happened

The FDA said in a letter dated Feb. 25 the restaurant sandwich chain is "engaged in a pattern of receiving and offering for sale adulterated fresh produce, specifically clover sprouts and cucumbers." The letter added Jimmy John's pattern dates back seven years across at least 17 states which implies control mechanisms in place for receiving fresh produce "are inadequate."

Most recently, 22 people in Iowa were infected with a strain of E. coli and the state's Department of Public Health interviewed 20 of these people. Each and everyone stated they ate at one or more Jimmy John's restaurants.

Why It's Important

In fact, the FDA noted it met with the company in May 2012 to discuss concerns related to its clover sprouts. But since then the company has been "implicated in three additional sprout-related outbreaks."

"Although you stated that corrective actions were implemented following the 2019 and 2012 outbreaks, you have not provided FDA with any information demonstrating long-term, sustainable corrections have been implemented throughout your organization to prevent this violation from recurring in the future," according to the letter.

According to Food Business News, the sandwich chain was given 15 days to respond to the letter.

Related Links

Chipotle Ditches Old Queso Blanco For New Recipe

Papa John's Reports Q4 Earnings Beat

 

Screengrab of JimmyJohns.com

 

Related Articles

View Comments and Join the Discussion!

Posted-In: food Food Business NewsNews Health Care Restaurants FDA Media General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com